- Home
- NRO vs CBIO Comparison
NRO vs CBIO Comparison
Compare NRO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- CBIO
- Stock Information
- Founded
- NRO 2003
- CBIO 2003
- Country
- NRO United States
- CBIO United States
- Employees
- NRO N/A
- CBIO N/A
- Industry
- NRO Finance/Investors Services
- CBIO
- Sector
- NRO Finance
- CBIO
- Exchange
- NRO Nasdaq
- CBIO Nasdaq
- Market Cap
- NRO 199.6M
- CBIO 173.5M
- IPO Year
- NRO N/A
- CBIO N/A
- Fundamental
- Price
- NRO $3.20
- CBIO $10.13
- Analyst Decision
- NRO
- CBIO Strong Buy
- Analyst Count
- NRO 0
- CBIO 5
- Target Price
- NRO N/A
- CBIO $25.60
- AVG Volume (30 Days)
- NRO 239.4K
- CBIO 127.5K
- Earning Date
- NRO 01-01-0001
- CBIO 11-23-2025
- Dividend Yield
- NRO 11.41%
- CBIO N/A
- EPS Growth
- NRO N/A
- CBIO N/A
- EPS
- NRO N/A
- CBIO N/A
- Revenue
- NRO N/A
- CBIO N/A
- Revenue This Year
- NRO N/A
- CBIO N/A
- Revenue Next Year
- NRO N/A
- CBIO N/A
- P/E Ratio
- NRO N/A
- CBIO N/A
- Revenue Growth
- NRO N/A
- CBIO N/A
- 52 Week Low
- NRO $2.51
- CBIO $10.13
- 52 Week High
- NRO $3.45
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- NRO 46.21
- CBIO 31.99
- Support Level
- NRO $3.19
- CBIO $10.96
- Resistance Level
- NRO $3.25
- CBIO $12.58
- Average True Range (ATR)
- NRO 0.04
- CBIO 0.74
- MACD
- NRO -0.01
- CBIO -0.10
- Stochastic Oscillator
- NRO 38.46
- CBIO 4.27
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.